Asthma - Market Insight, Epidemiology and Market Forecast - 2034

Market Overview

Asthma, a chronic inflammatory respiratory condition, continues to be a significant global health burden affecting millions of individuals. Characterized by airway inflammation, hyper-responsiveness, and intermittent airflow obstruction, the disease impacts individuals' quality of life, productivity, and healthcare systems. The condition manifests as wheezing, chest tightness, coughing, and shortness of breath, often triggered by environmental and lifestyle factors. With the increasing prevalence of asthma worldwide and advancements in treatment modalities, the asthma market is poised for substantial growth in the coming years.

In 2023, the asthma market size in the United States was approximately USD 13.8 billion, driven by the widespread adoption of innovative biologics and combination therapies. Across the 7MM (United States, EU4, UK, and Japan), the total market size was valued at USD 19 billion, with a projected CAGR of 3.9%, expected to reach approximately USD 30 billion by 2034. This growth is attributed to increasing awareness of the disease, improved diagnostic capabilities, and the launch of emerging therapeutics.

Key Market Drivers and Challenges

Market Drivers:

1. Innovative Therapies: The introduction of advanced biologics such as Tezspire (tezepelumab) and Dupixent (dupilumab) has revolutionized asthma management, particularly for severe cases.
2. Personalized Treatment: Tailored approaches based on disease severity and biomarkers have improved outcomes, especially in patients with Type 2 inflammation.
3. Rising Prevalence: Asthma affects over 55.1 million individuals in the 7MM, with the US accounting for nearly 26 million cases in 2023, driving market growth.
4. Emerging Drugs: The launch of Airsupra (albuterol/budesonide) in the US in 2023 and its anticipated rollout in the EU4 and the UK by 2025 and Japan by 2026 is set to significantly enhance the treatment landscape.

Market Challenges:

1. High Cost of Therapies: Biologics and combination therapies remain expensive, limiting accessibility for underinsured populations.
2. Reimbursement Issues: Variability in healthcare coverage across regions poses a challenge for market penetration.
3. Adherence Issues: The chronic nature of asthma often leads to non-adherence to long-term maintenance therapy.

Asthma Epidemiology

Asthma prevalence varies significantly across regions, driven by environmental factors, healthcare infrastructure, and genetic predisposition. The 7MM recorded 55.1 million diagnosed cases of asthma in 2023, segmented into:

• Age Distribution:
  • Pediatric Cases: ~11 million
  • Adult Cases: ~43 million
• Gender Distribution:
  • Females accounted for 56% of cases, reflecting hormonal and genetic influences.
• Severity Breakdown:
  • Intermittent Asthma: ~20 million cases
  • Persistent Asthma: ~35 million cases (mild, moderate, and severe subcategories)

Type-specific segmentation highlights a higher prevalence of Type 2 inflammation-driven asthma, emphasizing the need for targeted biologics.

Asthma Market Overview and Insights

Asthma, a chronic inflammatory respiratory condition, continues to be a significant global health burden affecting millions of individuals. Characterized by airway inflammation, hyper-responsiveness, and intermittent airflow obstruction, the disease impacts individuals' quality of life, productivity, and healthcare systems. The condition manifests as wheezing, chest tightness, coughing, and shortness of breath, often triggered by environmental and lifestyle factors. With the increasing prevalence of asthma worldwide and advancements in treatment modalities, the asthma market is poised for substantial growth in the coming years.

In 2023, the asthma market size in the United States was approximately USD 13.8 billion, driven by the widespread adoption of innovative biologics and combination therapies. Across the 7MM (United States, EU4, UK, and Japan), the total market size was valued at USD 19 billion, with a projected CAGR of 3.9%, expected to reach approximately USD 30 billion by 2034. This growth is attributed to increasing awareness of the disease, improved diagnostic capabilities, and the launch of emerging therapeutics.

Key Market Drivers and Challenges

Market Drivers:

1. Innovative Therapies: The introduction of advanced biologics such as Tezspire (tezepelumab) and Dupixent (dupilumab) has revolutionized asthma management, particularly for severe cases.
2. Personalized Treatment: Tailored approaches based on disease severity and biomarkers have improved outcomes, especially in patients with Type 2 inflammation.
3. Rising Prevalence: Asthma affects over 55.1 million individuals in the 7MM, with the US accounting for nearly 26 million cases in 2023, driving market growth.
4. Emerging Drugs: The launch of Airsupra (albuterol/budesonide) in the US in 2023 and its anticipated rollout in the EU4 and the UK by 2025 and Japan by 2026 is set to significantly enhance the treatment landscape.

Current Treatment Landscape

Key Therapeutic Classes:

1. Inhaled Corticosteroids (ICS): Foundation of asthma management, particularly for mild to moderate cases.
2. Combination Therapies (ICS/LABA/LAMA): Widely adopted for moderate to severe cases.
3. Biologics: Revolutionizing treatment for severe asthma by targeting specific inflammatory pathways.

Approved Biologics:

• Tezspire (tezepelumab): Inhibits TSLP, addressing multiple inflammatory pathways. Approved in the US, EU, and Japan.
• Dupixent (dupilumab): Targets IL-4/IL-13 pathways for Type 2 inflammation.
• Xolair (omalizumab): Effective for allergic asthma by inhibiting IgE.

Emerging Therapies

The pipeline for asthma therapeutics is robust, with several promising candidates in advanced clinical stages. Notable emerging therapies include:

1. GSK3511294 (Depemokimab): A long-acting anti-IL-5 monoclonal antibody with dosing every 26 weeks, offering enhanced convenience for severe asthma patients.
2. PT010 (AstraZeneca): A triple-combination inhaler targeting uncontrolled moderate to severe asthma.
3. Masitinib: A tyrosine kinase inhibitor targeting mast cell-driven inflammation.

These therapies are expected to address unmet needs, particularly in patients unresponsive to current treatments.

Asthma Market Value and Projections

The asthma market is expected to witness significant growth due to a combination of factors, including innovative treatments, increasing disease prevalence, and improved diagnostic capabilities.

• 2023 Market Value:
  • United States: USD 13.8 billion
  • 7MM: USD 19 billion
• 2034 Projections:
  • United States: USD 22 billion
  • 7MM: USD 30 billion
• CAGR (2024–2034): Approximately 3.9%

Among the EU countries, the UK accounted for the largest market size in 2023 at USD 1.3 billion, while Spain had the lowest market value at USD 0.4 billion. However, these dynamics are expected to shift with the launch of emerging therapies.

Recent Developments and Innovations

• 2023: FDA approval of Airsupra, a novel combination of albuterol and budesonide, marking a significant advancement in mild to moderate asthma management.
• 2024: Positive Phase IIIb results for Airsupra demonstrated a significant reduction in severe exacerbation risk, paving the way for broader adoption.

Asthma Market Segmentation and Regional Insights

Market Segments:

The asthma market is segmented by therapeutic class, severity of disease, type of patient, and mode of drug delivery, offering diverse treatment options tailored to specific patient needs.

1. By Therapeutic Class:
   • Inhaled Corticosteroids (ICS)
   • Combination Therapies (ICS/LABA/LAMA)
   • Biologics:
   • Leukotriene Receptor Antagonists (LTRA)
   • Oral and Intravenous Steroids
2. By Severity:
   • Intermittent Asthma
   • Persistent Asthma
     • Mild
     • Moderate
     • Severe
3. By Patient Type:
   • Pediatric
   • Adult
4. By Drug Delivery Mode:
   • Inhalers (MDIs and DPIs)
   • Oral Medications
   • Injectables

Regional Insights:

The asthma market is analyzed across the 7MM (United States, EU4, UK, and Japan), with significant regional variations in disease prevalence, treatment adoption, and market size.

1. United States:
2. EU4 (Germany, France, Italy, Spain) and the United Kingdom:
3. Spain
4. Japan

Market Growth Drivers by Region:

• United States
• Europe
• Japan

The asthma market is expected to grow significantly across all regions, with varying drivers like innovation, healthcare access, and disease prevalence shaping the dynamics.

Conclusion

The asthma market is at a pivotal juncture, with significant advancements in therapeutic options and personalized medicine reshaping the treatment paradigm. The introduction of innovative biologics and combination therapies is expected to drive market growth, addressing unmet needs and improving patient outcomes. With a projected market size of USD 30 billion by 2034 across the 7MM, the asthma therapeutics market remains a dynamic and innovation-driven space, offering substantial opportunities for stakeholders.